For Patients Full Prescribing Information With Medication Guide IFU Important Safety Information Contact a Representative

Breakthrough CINV exacts an emotional and physical toll on patients

Possible consequences of uncontrolled CINV may include:

Risk for medical complications such as malnutrition, weight loss, and electrolyte imbalances¹
Delays in their treatment plan or discontinuation of future chemotherapy cycles^2,3
Additional treatment, including reliance on rescue medications^1,4
Impact on quality of life by increasing the potential for hospitalizations and unscheduled visits for hydration^1,4
Increased utilization of healthcare resources that may include visits to the physician’s office or hospital that result in additional costs to patients^4,5
Increased risk of face-to-face contact, which puts immunocompromised patients at greater risk for contracting infections, such as COVID-19^6,7

It may be time to try an extended-release 5-HT₃ RA that is designed differently to work differently

5-HT₃ RA=5-hydroxytryptamine 3 receptor antagonist; CINV=chemotherapy-induced nausea and vomiting; COVID-19=coronavirus disease 2019.

Full 5-day efficacy⁸

Explore Phase 3 trial data

Robust safety profile^9-11

Review safety data

How well is CINV controlled?

See breakthrough CINV rates

INDICATION

SUSTOL is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens.

IMPORTANT SAFETY INFORMATION

Contraindications

SUSTOL is contraindicated in patients with hypersensitivity to granisetron, any of the components of SUSTOL, or any other 5-HT₃ receptor antagonist.

Warnings and Precautions

Injection site reactions (ISRs), including infection, bleeding, pain and tenderness, nodules, swelling, and induration, have occurred with SUSTOL. Monitor for ISRs following SUSTOL injection. Inform patients that some ISRs may occur 2 weeks or more after SUSTOL administration. In patients receiving antiplatelet agents or anticoagulants, consider the increased risk of bruising or severe hematoma prior to the use of SUSTOL.

Monitor for constipation and decreased bowel activity and consider optimizing patients’ current bowel regimens used for managing preexisting constipation. Instruct patients to seek immediate medical care if signs and symptoms of ileus occur.

Hypersensitivity reactions have been reported and may occur up to 7 days or longer following SUSTOL administration and may have an extended course. If a reaction occurs, administer appropriate treatment and monitor until signs and symptoms resolve.

Serotonin syndrome has been reported with 5-HT₃ receptor antagonists alone but particularly with concomitant use of serotonergic drugs.

Use in Specific Populations

Avoid SUSTOL in patients with severe renal impairment. In patients with moderate renal impairment, administer SUSTOL not more frequently than once every 14 days.

Adverse Reactions

Most common adverse reactions (≥3%) are injection site reactions, constipation, fatigue, headache, diarrhea, abdominal pain, insomnia, dyspepsia, dizziness, asthenia, and gastroesophageal reflux.

Report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Report side effects to Heron at 1-844-437-6611.

Please see full Prescribing Information, including Medication Guide.

References:

Hawkins, et al. Clin J Oncol Nurs. 2009.
Van Laar, et al. Support Care Cancer. 2015.
Neymark, et al. Support Care Cancer. 2005.
Burke, et al. Support Care Cancer. 2011.
Schwartzberg, et al. Am Health Drug Benefits. 2015.
Thom, et al. Clin Infect Dis. 2013.
National Cancer Institute. Updated November 4, 2021. Accessed November 4, 2021. https://www.cancer.gov/ about-cancer/coronavirus/coronavirus-cancer-patient-information#if-i-have-cancer-am-i-at-higher-risk-of-getting-covid-19.
SUSTOL [prescribing information]. Heron Therapeutics, Inc., 2023.
Data on File [C2006-01]. Heron Therapeutics, Inc.
Data on File [C2013-01]. Heron Therapeutics, Inc.
Gabrail, et al. Cancer Manag Res. 2015.